Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy ...
Vicore plans to leverage the benefits of Fast Track designation which include more frequent communications with FDA as well as the potential for Accelerated Approval and Priority Review.
The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...
Alterity plans to seek US FDA fast-track approval after posting positive phase II results for multiple system atrophy treatment. Alterity shares soared up to 112% this morning after the company ...
Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...